Jazz Pharmaceuticals PLC Q1 2021 Earnings Call Summary

The following is excerpted from the question-and-answer section of the transcript.

Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst : A question on the Xywav switch. Is there any reason to think that initial adopters of Xywav represent low-hanging fruit and that you could see a slowing from here? Or can we take this as a sign of momentum that should continue adding about 2,000 patients per quarter?

Question: Gary Jay Nachman - BMO Capital Markets Equity Research - Analyst : Regarding the payer access for Xywav in narcolepsy, we've heard from a few physicians that in some cases, it could be challenging to get Xywav if a patient doesn't have a documented history of hypertension, rather than as a preventative measure to prevent the CV issues from happening. So how are you getting around that potential hurdle if it is a hurdle for you? I mean it sounds like you feel very good about where access is at this point. But is that something that the physicians sort of have to get around in order to get the patients on it?

Question: Gregory B. Gilbert - Truist Securities, Inc., Research Division - Analyst : On 458, are FDA actions and interactions providing you with more confidence on an approval versus a typical situation given the unique circumstances of the supply situation? And do you have any updated thoughts on your former partners' ability to compete with, let's call it, the older product in the U.S. or around the world?